Next Article in Journal
Informing Decision Makers Seeking to Improve Vaccination Programs: Case-Study Serbia
Previous Article in Journal
Modeling Long-Term Health and Economic Implications of New Treatment Strategies for Parkinson’s Disease: An Individual Patient Simulation Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 9
Issue 1
10.1080/20016689.2021.1929757
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of Health Technology Assessment on Prescribing Patterns of Inhaled Fixed-Dose Combination Triple Therapy in Chronic Obstructive Pulmonary Disease

by
Jennifer Cook
1,
Chloe Bloom
2,
Jen Lewis
3,
Zoe Marjenberg
3,
Jaime Hernando Platz
1 and
Sue Langham
3,*
1
TA Cardio Metabolism Respiratory Global Market Access, Boehringer Ingelheim GmbH, Ingelheim Am Rhein, Germany
2
Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK
3
Maverex Limited, Manchester, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2021, 9(1), 1929757; https://doi.org/10.1080/20016689.2021.1929757
Submission received: 14 December 2020 / Revised: 3 May 2021 / Accepted: 7 May 2021 / Published: 2 June 2021

Abstract

Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications. Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies. Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated. Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®). Main outcome measure: HTA restrictions and prescribing rates (days of therapy). Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake. Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources.
Keywords: chronic obstructive pulmonary disease; fixed-dose combination; health technology assessment; triple therapy chronic obstructive pulmonary disease; fixed-dose combination; health technology assessment; triple therapy

Share and Cite

MDPI and ACS Style

Cook, J.; Bloom, C.; Lewis, J.; Marjenberg, Z.; Platz, J.H.; Langham, S. Impact of Health Technology Assessment on Prescribing Patterns of Inhaled Fixed-Dose Combination Triple Therapy in Chronic Obstructive Pulmonary Disease. J. Mark. Access Health Policy 2021, 9, 1929757. https://doi.org/10.1080/20016689.2021.1929757

AMA Style

Cook J, Bloom C, Lewis J, Marjenberg Z, Platz JH, Langham S. Impact of Health Technology Assessment on Prescribing Patterns of Inhaled Fixed-Dose Combination Triple Therapy in Chronic Obstructive Pulmonary Disease. Journal of Market Access & Health Policy. 2021; 9(1):1929757. https://doi.org/10.1080/20016689.2021.1929757

Chicago/Turabian Style

Cook, Jennifer, Chloe Bloom, Jen Lewis, Zoe Marjenberg, Jaime Hernando Platz, and Sue Langham. 2021. "Impact of Health Technology Assessment on Prescribing Patterns of Inhaled Fixed-Dose Combination Triple Therapy in Chronic Obstructive Pulmonary Disease" Journal of Market Access & Health Policy 9, no. 1: 1929757. https://doi.org/10.1080/20016689.2021.1929757

APA Style

Cook, J., Bloom, C., Lewis, J., Marjenberg, Z., Platz, J. H., & Langham, S. (2021). Impact of Health Technology Assessment on Prescribing Patterns of Inhaled Fixed-Dose Combination Triple Therapy in Chronic Obstructive Pulmonary Disease. Journal of Market Access & Health Policy, 9(1), 1929757. https://doi.org/10.1080/20016689.2021.1929757

Article Metrics

Back to TopTop